| 1 |
33063648 | Molecular dynamic mechanism(s) of inhibition of bioactive antiviral phytochemical compounds targeting cytochrome P450 3A4 and P-glycoprotein. | 2022 Feb |
1 |
| 2 |
33032513 | Suppression of HIV-1 Viral Replication by Inhibiting Drug Efflux Transporters in Activated Macrophages. | 2021 |
1 |
| 3 |
33759544 | Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients. | 2021 Apr |
2 |
| 4 |
34426410 | Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation. | 2021 Oct |
1 |
| 5 |
33312066 | Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations. | 2020 Oct 2 |
1 |
| 6 |
31028820 | Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant - Soluplus. | 2019 Jun 15 |
1 |
| 7 |
31262902 | Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition. | 2019 Jul |
1 |
| 8 |
31481446 | Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices. | 2019 Nov |
2 |
| 9 |
28676669 | Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. | 2018 Feb |
6 |
| 10 |
24727459 | Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir. | 2014 Apr 10 |
4 |
| 11 |
23528223 | Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children. | 2013 Jun 10 |
2 |
| 12 |
20551216 | Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. | 2010 Aug |
3 |
| 13 |
19207033 | ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. | 2009 Feb |
1 |
| 14 |
19960055 | Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. | 2009 |
3 |
| 15 |
18183034 | Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. | 2008 Jul |
2 |
| 16 |
17324111 | Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. | 2007 Mar |
1 |
| 17 |
17591027 | Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. | 2007 |
2 |
| 18 |
17890284 | Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. | 2007 Nov |
2 |
| 19 |
12700464 | Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. | 2003 May 2 |
4 |
| 20 |
12902797 | The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. | 2003 Aug 15 |
1 |
| 21 |
14711599 | No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. | 2003 Dec 9 |
2 |